Thomas Pietschmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/856179/publications.pdf

Version: 2024-02-01

146 papers 15,383 citations

51 h-index 120 g-index

161 all docs

161 docs citations

161 times ranked 14284 citing authors

#	Article	IF	CITATIONS
1	Sandacrabins – Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium**. Chemistry - A European Journal, 2022, 28, e202104484.	3.3	10
2	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 2022, 55, 341-354.e7.	14.3	21
3	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. Virus Evolution, 2022, 8, veac007.	4.9	10
4	Differential interferon- $\hat{l}\pm$ subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	33
5	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. Journal of Virology, 2022, 96, e0199521.	3.4	4
6	IRIS: Infection with RespIratory Syncytial Virus in infants—a prospective observational cohort study. BMC Pulmonary Medicine, 2022, 22, 88.	2.0	6
7	Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients. Antimicrobial Resistance and Infection Control, 2022, 11 , .	4.1	3
8	Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements. Journal of Virology, 2021, 95, .	3.4	13
9	A condensate-hardening drug blocks RSV replication in vivo. Nature, 2021, 595, 596-599.	27.8	121
10	Magnesium Complexes of Ladanein: A Beneficial Strategy for Stabilizing Polyphenolic Antivirals. European Journal of Inorganic Chemistry, 2021, 2021, 2764-2772.	2.0	1
11	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. Gut, 2021, 70, 1734-1745.	12.1	15
12	Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes. Cells, 2021, 10, 3019.	4.1	10
13	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036830.	6.2	40
14	Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis. Journal of Virology, 2020, 94, .	3.4	30
15	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE, 2020, 15, e0236447.	2.5	7
16	Liver-expressed <i>Cd302</i> and <i>Cr11</i> limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	10.3	23
17	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
18	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathogens, 2020, 16, e1008554.	4.7	25

#	Article	IF	Citations
19	Controlled Functional Zonation of Hepatocytes <i>In Vitro</i> by Engineering of Wnt Signaling. ACS Synthetic Biology, 2020, 9, 1638-1649.	3.8	13
20	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut, 2020, 69, 1659-1666.	12.1	18
21	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Research, 2020, 177, 104774.	4.1	30
22	Protecting-Group-Mediated Diastereoselective Synthesis of C4′-Methylated Uridine Analogs and Their Activity against the Human Respiratory Syncytial Virus. Journal of Organic Chemistry, 2020, 85, 4267-4278.	3.2	8
23	C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. Journal of Hepatology, 2020, 73, 549-558.	3.7	35
24	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Medical Microbiology and Immunology, 2020, 209, 499-514.	4.8	6
25	Synthesis of 4′/5′-Spirocyclopropanated Uridine and <scp>d</scp> -Xylouridine Derivatives and Their Activity against the Human Respiratory Syncytial Virus. Organic Letters, 2019, 21, 6966-6971.	4.6	18
26	Hepatitis C Virus. Trends in Microbiology, 2019, 27, 379-380.	7.7	33
27	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells, 2019, 8, 610.	4.1	5
28	HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells, 2019, 8, 233.	4.1	41
29	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. Viruses, 2019, 11, 275.	3.3	7
30	Physicochemical Properties Govern the Activity of Potent Antiviral Flavones. ACS Omega, 2019, 4, 4871-4887.	3.5	11
31	Cohort Profile: The LoewenKIDS Study – life-course perspective on infections, the microbiome and the development of the immune system in early childhood. International Journal of Epidemiology, 2019, 48, 1042-1043h.	1.9	3
32	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Journal of Hepatology, 2019, 70, 1082-1092.	3.7	15
33	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
34	Hepatitis E virus replication and interferon responses in human placental cells. Hepatology Communications, 2018, 2, 173-187.	4.3	40
35	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research, 2018, 248, 53-62.	2.2	124
36	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9

3

#	Article	IF	CITATIONS
37	CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. Viruses, 2018, 10, 207.	3.3	13
38	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathogens, 2018, 14, e1007111.	4.7	46
39	Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease. Antimicrobial Resistance and Infection Control, 2018, 7, 21.	4.1	4
40	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, 139, 129-137.	4.1	5
41	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. Molecular and Cellular Proteomics, 2017, 16, S75-S91.	3.8	53
42	Immune protection against reinfection with nonprimate hepacivirus. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2430-E2439.	7.1	42
43	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. Journal of Hepatology, 2017, 67, 480-489.	3.7	51
44	Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. MBio, 2017, 8, .	4.1	31
45	Virucidal Activity of World Health Organization–Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. Journal of Infectious Diseases, 2017, 215, 902-906.	4.0	151
46	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Research, 2017, 147, 19-28.	4.1	28
47	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. Journal of Virology, 2017, 91, .	3.4	21
48	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters, 2017, 6, 935-940.	4.8	4
49	Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. Journal of Virology, 2017, 91, .	3.4	19
50	Flunarizine prevents hepatitis C virus membrane fusion in a genotypeâ€dependent manner by targeting the potential fusion peptide within E1. Hepatology, 2016, 63, 49-62.	7.3	64
51	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. Cell Host and Microbe, 2016, 20, 443-457.	11.0	46
52	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. Journal of Virology, 2016, 90, 10670-10681.	3.4	27
53	Hepatitis C virus plays hide and seek with neutralizing antibodies. Hepatology, 2016, 64, 1840-1842.	7. 3	7
54	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. Hepatology, 2016, 64, 2274-2276.	7.3	7

#	Article	IF	CITATIONS
55	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. MBio, 2016, 7, .	4.1	13
56	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2132-2139.	3.2	75
57	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. Journal of Virology, 2016, 90, 5075-5089.	3.4	4
58	Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. Journal of Virology, 2016, 90, 3065-3073.	3.4	22
59	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8 ⁺ T Cell Response by Selection of Altered Epitope Processing. Journal of Virology, 2016, 90, 33-42.	3.4	16
60	Decoding protein networks during virus entry by quantitative proteomics. Virus Research, 2016, 218, 25-39.	2.2	24
61	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut, 2016, 65, 2029-2034.	12.1	21
62	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. PLoS Pathogens, 2016, 12, e1005568.	4.7	26
63	Hepatitis C Virus Stimulates Murine CD8î±-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathogens, 2016, 12, e1005736.	4.7	4
64	Cell culture-derived HCV cannot infect synovial fibroblasts. Scientific Reports, 2015, 5, 18043.	3.3	1
65	Interferonâ€inducible cholesterolâ€25â€hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology, 2015, 62, 702-714.	7.3	78
66	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses, 2015, 7, 3995-4046.	3.3	42
67	Efficient Virus Assembly, but Not Infectivity, Determines the Magnitude of Hepatitis C Virus-Induced Interferon Alpha Responses of Plasmacytoid Dendritic Cells. Journal of Virology, 2015, 89, 3200-3208.	3.4	9
68	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Reports, 2015, 12, 864-878.	6.4	50
69	Clinical course of infection and viral tissue tropism of hepatitis C virus–like nonprimate hepaciviruses in horses. Hepatology, 2015, 61, 447-459.	7.3	116
70	Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons. Journal of Virology, 2015, 89, 3833-3845.	3.4	23
71	Mechanisms of Methods for Hepatitis C Virus Inactivation. Applied and Environmental Microbiology, 2015, 81, 1616-1621.	3.1	46
72	Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. Journal of Hepatology, 2015, 63, 813-821.	3.7	28

#	Article	IF	CITATIONS
73	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. Journal of General Virology, 2015, 96, 2636-2642.	2.9	19
74	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS ONE, 2015, 10, e0134529.	2.5	30
75	A molecular tweezer antagonizes seminal amyloids and HIV infection. ELife, 2015, 4, .	6.0	71
76	In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. Gut, 2014, 63, 1375-1377.	12.1	2
77	Natural reservoirs for homologs of hepatitis C virus. Emerging Microbes and Infections, 2014, 3, 1-9.	6.5	88
78	Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion. Viruses, 2014, 6, 1149-1187.	3.3	56
79	A circuit of paracrine signals between liver sinusoid endothelial cells and hepatocytes regulates hepatitis C virus replication. Hepatology, 2014, 59, 363-365.	7.3	O
80	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. Journal of Virology, 2014, 88, 667-678.	3.4	2
81	The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets. Digestive Diseases, 2014, 32, 525-537.	1.9	3,128
82	Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. PLoS ONE, 2014, 9, e102235.	2.5	8
83	Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly. Journal of Virology, 2014, 88, 1433-1446.	3.4	88
84	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology, 2014, 59, 78-88.	7.3	40
85	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut, 2014, 63, 1137-1149.	12.1	148
86	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro in v	7.3	50
87	Role of Hypervariable Region 1 for the Interplay of Hepatitis C Virus with Entry Factors and Lipoproteins. Journal of Virology, 2014, 88, 12644-12655.	3.4	42
88	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. Antiviral Research, 2014, 110, 52-59.	4.1	12
89	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. Hepatology, 2014, 60, 508-520.	7.3	7
90	Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology, 2014, 59, 24-34.	7.3	54

#	Article	IF	Citations
91	Entry and replication of recombinant hepatitis C viruses in cell culture. Methods, 2013, 59, 233-248.	3.8	46
92	Hepatitis C Virus Replication in Mouse Cells Is Restricted by IFN-Dependent and -Independent Mechanisms. Gastroenterology, 2013, 145, 1414-1423.e1.	1.3	30
93	Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO Journal, 2013, 32, 3055-3065.	7.8	177
94	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Current Hepatitis Reports, 2013, 12, 200-213.	0.3	7
95	Two pathogen reduction technologiesâ€"methylene blue plus light and shortwave ultraviolet lightâ€"effectively inactivate hepatitis C virus in blood products. Transfusion, 2013, 53, 1010-1018.	1.6	54
96	Cell Culture Systems for Hepatitis C Virus. Current Topics in Microbiology and Immunology, 2013, 369, 17-48.	1.1	72
97	Characterization of the inhibition of hepatitis C virus entry by (i>In vitro (i>-generated and patient-derived oxidized low-density lipoprotein. Hepatology, 2013, 57, 1716-1724.	7.3	16
98	Hepatitis C virus NS5B polymerase primes innate immune signaling. Hepatology, 2013, 57, 1275-1277.	7.3	2
99	Hepatitis C Virus p7 is Critical for Capsid Assembly and Envelopment. PLoS Pathogens, 2013, 9, e1003355.	4.7	102
100	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. Journal of Infectious Diseases, 2013, 208, 1943-1952.	4.0	47
101	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. Journal of Infectious Diseases, 2013, 207, 281-287.	4.0	57
102	Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment. Journal of Virology, 2013, 87, 13297-13306.	3.4	18
103	Subcellular Localization and Function of an Epitope-Tagged p7 Viroporin in Hepatitis C Virus-Producing Cells. Journal of Virology, 2013, 87, 1664-1678.	3.4	42
104	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology, 2013, 57, 492-504.	7.3	66
105	MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles. PLoS Pathogens, 2012, 8, e1002829.	4.7	110
106	Escape from a Dominant HLA-B*15-Restricted CD8 ⁺ T Cell Response against Hepatitis C Virus Requires Compensatory Mutations outside the Epitope. Journal of Virology, 2012, 86, 991-1000.	3.4	21
107	A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. Gastroenterology, 2012, 143, 213-222.e5.	1.3	111
108	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. Gastroenterology, 2012, 143, 223-233.e9.	1.3	66

#	Article	IF	CITATIONS
109	Total Synthesis of a Noricumazoleâ€A Library and Evaluation of HCV Inhibition. Chemistry - A European Journal, 2012, 18, 9083-9090.	3.3	19
110	Bile Acids Specifically Increase Hepatitis C Virus RNA-Replication. PLoS ONE, 2012, 7, e36029.	2.5	23
111	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine, 2011, 17, 589-595.	30.7	631
112	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Research, 2011, 89, 136-148.	4.1	41
113	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 2011, 54, 1947-1955.	7.3	255
114	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. Journal of Virology, 2011, 85, 7613-7621.	3.4	40
115	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. PLoS Pathogens, 2011, 7, e1002029.	4.7	23
116	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. Journal of Infectious Diseases, 2011, 204, 1830-1838.	4.0	90
117	NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus. Journal of Biological Chemistry, 2010, 285, 31446-31461.	3.4	119
118	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. Journal of Virology, 2010, 84, 5751-5763.	3.4	201
119	Mouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell Line. Journal of Virology, 2010, 84, 964-975.	3.4	50
120	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. Journal of Infectious Diseases, 2010, 201, 1859-1866.	4.0	72
121	Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. PLoS Pathogens, 2010, 6, e1000978.	4.7	109
122	Hepatitis C Virus P7—A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy. Viruses, 2010, 2, 2078-2095.	3.3	44
123	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. Gastroenterology, 2010, 138, 1875-1884.	1.3	68
124	Virucidal activity of 2 alcohol-based formulations proposed as hand rubs byÂthe World Health Organization. American Journal of Infection Control, 2010, 38, 66-68.	2.3	34
125	Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations. PLoS Pathogens, 2009, 5, e1000475.	4.7	116
126	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. Journal of Biological Chemistry, 2009, 284, 17657-17667.	3.4	79

#	Article	IF	Citations
127	Characterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using trans -Complementation. Journal of Virology, 2009, 83, 11682-11693.	3.4	65
128	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 295-308.	16.8	345
129	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 447.	16.8	1
130	Full-Length Infectious HCV Chimeras. Methods in Molecular Biology, 2009, 510, 347-359.	0.9	8
131	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. Journal of General Virology, 2009, 90, 48-58.	2.9	162
132	Efficient <i>trans</i> -Encapsidation of Hepatitis C Virus RNAs into Infectious Virus-Like Particles. Journal of Virology, 2008, 82, 7034-7046.	3.4	131
133	Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly. Journal of Biological Chemistry, 2008, 283, 28546-28562.	3.4	135
134	Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. PLoS Pathogens, 2007, 3, e103.	4.7	290
135	Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes. Journal of Virology, 2007, 81, 4591-4603.	3.4	198
136	The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells. Journal of Virology, 2007, 81, 588-598.	3.4	201
137	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology, 2007, 46, 330-338.	7.3	127
138	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology, 2007, 46, 1722-1731.	7. 3	222
139	High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor Bl. Journal of Biological Chemistry, 2006, 281, 18285-18295.	3.4	186
140	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology, 2006, 43, 592-601.	7.3	150
141	Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses. Journal of Virology, 2006, 80, 5308-5320.	3.4	363
142	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7408-7413.	7.1	651
143	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	30.7	2,561
144	Novel Insights into Hepatitis C Virus Replication and Persistence. Advances in Virus Research, 2004, 63, 71-180.	2.1	243

#	Article	IF	CITATIONS
145	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14416-14421.	7.1	244
146	Foamy Virus Capsids Require the Cognate Envelope Protein for Particle Export. Journal of Virology, 1999, 73, 2613-2621.	3.4	152